Health and Medicine
Jan. 10, 2020—D. Borden Lacy and colleagues used cryo-electron microscopy to define the structure of a C. diff toxin, providing a framework for the design of novel therapeutics.
Dec. 17, 2019—A newly identified protein interaction that affects cell cycle regulation may be an attractive target for cancer therapy.
Dec. 16, 2019—To study the dynamics of structural proteins in the heart, Vanderbilt investigators generated a cellular tool they expect will be useful for screening drugs that affect heart muscle contraction.
Dec. 12, 2019—VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.
Dec. 12, 2019—Vanderbilt neurologists have identified a protein modification that could be targeted to reduce neuronal excitability in epilepsy.
Dec. 12, 2019—A drug used to treat and prevent HIV/AIDS is showing promise as a potential therapy for Alzheimer’s disease.
Dec. 12, 2019—Antibody discovery and vaccine development research may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues.
Dec. 12, 2019—A computational method that uses hospital billing codes and electronic health records can identify genetic disease cases before clinical teams do.
Dec. 5, 2019—Poorly functioning AMPARs have been linked to a wide range of neurological and psychiatric disorders including seizures, Alzheimer’s disease, major depression and autism spectrum disorder. Understanding how AMPARs are formed and operate is essential for the rational design of pharmacological compounds that, by tuning AMPAR activity up or down, could improve treatment of these conditions.
Dec. 4, 2019—The identification of a protein important for insulin synthesis may hold clues for understanding the pathogenesis of diabetes.
Nov. 27, 2019—To explore how fear becomes entrenched, VUMC researchers traveled down the precise neuronal pathways in the brains of mice that trigger fear responses, and which normally extinguish the behaviors once the danger has passed.
Nov. 21, 2019—Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications.